

Paraguay

Population 2015

6.6 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.26 (0.22–0.31)	4 (3.3–4.7)
Mortality (HIV+TB only)	0.035 (<0.01–0.11)	0.53 (0.03–1.7)
Incidence (includes HIV+TB)	2.7 (2.3–3.1)	41 (35–47)
Incidence (HIV+TB only)	0.24 (0.2–0.28)	3.6 (3–4.2)
Incidence (MDR/RR-TB)**	0.087 (0.044–0.13)	1.3 (0.66–2)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	0.15 (0.095–0.2)	0.71 (0.4–1)	0.86 (0.5–1.2)
Males	0.15 (0.1–0.19)	1.7 (1.3–2.1)	1.9 (1.4–2.3)
Total	0.3 (0.23–0.36)	2.4 (2.2–2.6)	2.7 (2.3–3.1)

TB case notifications, 2015

Total cases notified	2 530
Total new and relapse	2 353
- % tested with rapid diagnostics at time of diagnosis	14%
- % with known HIV status	87%
- % pulmonary	91%
- % bacteriologically confirmed among pulmonary	78%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.11 (0.08–0.15)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	181	9%
- on antiretroviral therapy	150	83%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			76 (26–130)
Estimated % of TB cases with MDR/RR-TB	0.9% (0–2.2)	15% (4–25)	
% notified tested for rifampicin resistance	26%	49%	758
MDR/RR-TB cases tested for resistance to second-line drugs			3
Laboratory-confirmed cases		MDR/RR-TB: 13, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 15, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	71%	2 240
Previously treated cases, excluding relapse, registered in 2014	51%	164
HIV-positive TB cases, all types, registered in 2014	39%	179
MDR/RR-TB cases started on second-line treatment in 2013	33%	6
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	7%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	30% (27–33)

TB financing, 2016

National TB budget (US\$ millions)	24
Funding source: 15% domestic, 9% international, 77% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence
Notified (new and relapse)
Incidence (HIV+TB only)

Notified cases by age group and sex, 2015




Treatment success rate (%)



New and relapse
Retreatment, excluding relapse
HIV-positive MDR/RR-TB XDR-TB

Total budget (US\$ millions)



Unfunded
Funded internationally
Funded domestically